- Practice your CELG trading strategies and win cash in our stock game.
NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Friday as it is currently trading at $67.31, above its previous 52-week high of $67.01 with 1.2 million shares traded as of 10:46 a.m. ET. Average volume has been 4.2 million shares over the past 30 days. Celgene has a market cap of $30 billion and is part of the health care sector and drugs industry. Shares are up 10.4% year to date as of the close of trading on Thursday. Celgene Corporation, an integrated biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. The company has a P/E ratio of 29.8, below the average drugs industry P/E ratio of 30.1 and above the S&P 500 P/E ratio of 17.7.